Suppr超能文献

金属配合物加速抗 COVID-19 选项的全面调查:任务与试验。

A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes-Tasks and Trials.

机构信息

Department of Research and Innovation, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 602105, Tamil Nadu, India.

Department of Bioresources and Food Science, Institute of Natural Science and Agriculture, Konkuk University, Gwangjin-gu, Seoul 05029, Republic of Korea.

出版信息

Molecules. 2023 Apr 10;28(8):3354. doi: 10.3390/molecules28083354.

Abstract

Contemporary pharmacology dating back to the late 19th/early 20th centuries has benefitted largely from the incorporation of metal complexes. Various biological attributes have been successfully realized using metal/metal complex-based drugs. Among anticancer, antimicrobial, and antiviral applications, anticancer applications have extracted the maximum benefit from the metal complex, Cisplatin. The following review has compiled the various antiviral benefits harnessed through inputs from metal complexes. As a result of exploiting the pharmacological aspects of metal complexes, the anti-COVID-19 deliverables have been summarized. The challenges ahead, the gaps in this research area, the need to improvise incorporating nanoaspects in metal complexes, and the need to test metal complex-based drugs in clinical trials have been discussed and deliberated. The pandemic shook the entire world and claimed quite a percentage of the global population. Metal complex-based drugs are already established for their antiviral property with respect to enveloped viruses and extrapolating them for COVID-19 can be an effective way to manipulate drug resistance and mutant issues that the current anti-COVID-19 drugs are facing.

摘要

当代药理学可以追溯到 19 世纪末/20 世纪初,在很大程度上受益于金属配合物的应用。通过使用基于金属/金属配合物的药物,可以成功实现各种生物学特性。在抗癌、抗菌和抗病毒应用中,抗癌应用从金属配合物顺铂中获得了最大的收益。以下综述总结了通过金属配合物的投入所获得的各种抗病毒益处。由于利用了金属配合物的药理学特性,总结了抗 COVID-19 的成果。讨论和审议了未来的挑战、该研究领域的差距、将纳米方面纳入金属配合物的必要性以及在临床试验中测试基于金属配合物的药物的必要性。这场大流行震撼了整个世界,夺走了相当一部分全球人口的生命。基于金属配合物的药物已经因其对包膜病毒的抗病毒特性而被确立,将它们外推用于 COVID-19 可能是一种有效控制当前抗 COVID-19 药物所面临的耐药性和突变问题的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e07/10143858/24d5794ad8cf/molecules-28-03354-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验